The utility of magnetic resonance imaging in cardiac tissue regeneration trials

Valentin Fuster, Javier Sanz, Juan Viles Gonzalez, Sanjay Rajagopalan

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

The past decade has seen the emergence of paradigm shifts in concepts involving cardiovascular tissue regeneration, including the idea that adult stem cells originate in hematopoietic or bone marrow cells, the belief that even adult organs, such as the heart and nervous system, are capable of post-mitotic regeneration, and the concept of inherent plasticity in cells that have undergone limited lineage differentiation. There has consequently been a flurry of proposed regenerative strategies, and safety and limited efficacy data from both animal and limited human trials have been presented. The drive to push these advances from the bench to the bedside has created a unique environment where the therapeutic agents, delivery approaches, and methods of measuring efficacy (often imaging technology) are evolving practically in parallel. The encouraging results of recent cell-therapy trials should therefore be assessed cautiously and in consonance with an understanding of the advantages and limitations of delivery strategies and end points. Arguably, the use of imaging technologies to evaluate surrogate end points might help overcome the difficulty posed by large sample sizes required for hard end point trials in cardiovascular therapeutics. Cardiac magnetic resonance imaging is one of the most sensitive techniques available to assess spatial and temporal changes following local or systemic therapies, and the availability of a bevy of complementary techniques enables interrogation of physiology, morphology, and metabolism in one setting. We contend that cardiac magnetic resonance imaging is ideally suited to assess response to myocardial regeneration therapy and can be exploited to yield valuable insights into the mechanism of action of myocardial regeneration therapies.

Original languageEnglish
JournalNature Clinical Practice Cardiovascular Medicine
Volume3
Issue numberSUPPL. 1
DOIs
StatePublished - Mar 1 2006
Externally publishedYes

Fingerprint

Regeneration
Magnetic Resonance Imaging
Technology
Therapeutics
Adult Stem Cells
Cell- and Tissue-Based Therapy
Bone Marrow Cells
Sample Size
Nervous System
Biomarkers
Safety

Keywords

  • Cell therapy
  • CMRI
  • Echocardiography
  • Heart failure
  • Myocardial infarction

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

The utility of magnetic resonance imaging in cardiac tissue regeneration trials. / Fuster, Valentin; Sanz, Javier; Viles Gonzalez, Juan; Rajagopalan, Sanjay.

In: Nature Clinical Practice Cardiovascular Medicine, Vol. 3, No. SUPPL. 1, 01.03.2006.

Research output: Contribution to journalArticle

Fuster, Valentin ; Sanz, Javier ; Viles Gonzalez, Juan ; Rajagopalan, Sanjay. / The utility of magnetic resonance imaging in cardiac tissue regeneration trials. In: Nature Clinical Practice Cardiovascular Medicine. 2006 ; Vol. 3, No. SUPPL. 1.
@article{06e0c722c4f946058e0217f8322402b2,
title = "The utility of magnetic resonance imaging in cardiac tissue regeneration trials",
abstract = "The past decade has seen the emergence of paradigm shifts in concepts involving cardiovascular tissue regeneration, including the idea that adult stem cells originate in hematopoietic or bone marrow cells, the belief that even adult organs, such as the heart and nervous system, are capable of post-mitotic regeneration, and the concept of inherent plasticity in cells that have undergone limited lineage differentiation. There has consequently been a flurry of proposed regenerative strategies, and safety and limited efficacy data from both animal and limited human trials have been presented. The drive to push these advances from the bench to the bedside has created a unique environment where the therapeutic agents, delivery approaches, and methods of measuring efficacy (often imaging technology) are evolving practically in parallel. The encouraging results of recent cell-therapy trials should therefore be assessed cautiously and in consonance with an understanding of the advantages and limitations of delivery strategies and end points. Arguably, the use of imaging technologies to evaluate surrogate end points might help overcome the difficulty posed by large sample sizes required for hard end point trials in cardiovascular therapeutics. Cardiac magnetic resonance imaging is one of the most sensitive techniques available to assess spatial and temporal changes following local or systemic therapies, and the availability of a bevy of complementary techniques enables interrogation of physiology, morphology, and metabolism in one setting. We contend that cardiac magnetic resonance imaging is ideally suited to assess response to myocardial regeneration therapy and can be exploited to yield valuable insights into the mechanism of action of myocardial regeneration therapies.",
keywords = "Cell therapy, CMRI, Echocardiography, Heart failure, Myocardial infarction",
author = "Valentin Fuster and Javier Sanz and {Viles Gonzalez}, Juan and Sanjay Rajagopalan",
year = "2006",
month = "3",
day = "1",
doi = "10.1038/ncpcardio0418",
language = "English",
volume = "3",
journal = "Nature Reviews Cardiology",
issn = "1759-5002",
publisher = "Nature Publishing Group",
number = "SUPPL. 1",

}

TY - JOUR

T1 - The utility of magnetic resonance imaging in cardiac tissue regeneration trials

AU - Fuster, Valentin

AU - Sanz, Javier

AU - Viles Gonzalez, Juan

AU - Rajagopalan, Sanjay

PY - 2006/3/1

Y1 - 2006/3/1

N2 - The past decade has seen the emergence of paradigm shifts in concepts involving cardiovascular tissue regeneration, including the idea that adult stem cells originate in hematopoietic or bone marrow cells, the belief that even adult organs, such as the heart and nervous system, are capable of post-mitotic regeneration, and the concept of inherent plasticity in cells that have undergone limited lineage differentiation. There has consequently been a flurry of proposed regenerative strategies, and safety and limited efficacy data from both animal and limited human trials have been presented. The drive to push these advances from the bench to the bedside has created a unique environment where the therapeutic agents, delivery approaches, and methods of measuring efficacy (often imaging technology) are evolving practically in parallel. The encouraging results of recent cell-therapy trials should therefore be assessed cautiously and in consonance with an understanding of the advantages and limitations of delivery strategies and end points. Arguably, the use of imaging technologies to evaluate surrogate end points might help overcome the difficulty posed by large sample sizes required for hard end point trials in cardiovascular therapeutics. Cardiac magnetic resonance imaging is one of the most sensitive techniques available to assess spatial and temporal changes following local or systemic therapies, and the availability of a bevy of complementary techniques enables interrogation of physiology, morphology, and metabolism in one setting. We contend that cardiac magnetic resonance imaging is ideally suited to assess response to myocardial regeneration therapy and can be exploited to yield valuable insights into the mechanism of action of myocardial regeneration therapies.

AB - The past decade has seen the emergence of paradigm shifts in concepts involving cardiovascular tissue regeneration, including the idea that adult stem cells originate in hematopoietic or bone marrow cells, the belief that even adult organs, such as the heart and nervous system, are capable of post-mitotic regeneration, and the concept of inherent plasticity in cells that have undergone limited lineage differentiation. There has consequently been a flurry of proposed regenerative strategies, and safety and limited efficacy data from both animal and limited human trials have been presented. The drive to push these advances from the bench to the bedside has created a unique environment where the therapeutic agents, delivery approaches, and methods of measuring efficacy (often imaging technology) are evolving practically in parallel. The encouraging results of recent cell-therapy trials should therefore be assessed cautiously and in consonance with an understanding of the advantages and limitations of delivery strategies and end points. Arguably, the use of imaging technologies to evaluate surrogate end points might help overcome the difficulty posed by large sample sizes required for hard end point trials in cardiovascular therapeutics. Cardiac magnetic resonance imaging is one of the most sensitive techniques available to assess spatial and temporal changes following local or systemic therapies, and the availability of a bevy of complementary techniques enables interrogation of physiology, morphology, and metabolism in one setting. We contend that cardiac magnetic resonance imaging is ideally suited to assess response to myocardial regeneration therapy and can be exploited to yield valuable insights into the mechanism of action of myocardial regeneration therapies.

KW - Cell therapy

KW - CMRI

KW - Echocardiography

KW - Heart failure

KW - Myocardial infarction

UR - http://www.scopus.com/inward/record.url?scp=33644632216&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33644632216&partnerID=8YFLogxK

U2 - 10.1038/ncpcardio0418

DO - 10.1038/ncpcardio0418

M3 - Article

C2 - 16501625

AN - SCOPUS:33644632216

VL - 3

JO - Nature Reviews Cardiology

JF - Nature Reviews Cardiology

SN - 1759-5002

IS - SUPPL. 1

ER -